Endo fights FTC’s “back-door” challenge
The Federal Trade Commission is using the Impax case about an alleged 2010 no-authorised-generic agreement to attack a patent settlement made just last August, Endo Pharmaceuticals said in a successful bid last week to intervene in the agency’s administrative proceeding.
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10